Edition:
United Kingdom

People: Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

4.32USD
23 Aug 2019
Change (% chg)

$-0.13 (-2.92%)
Prev Close
$4.45
Open
$4.70
Day's High
$4.80
Day's Low
$4.25
Volume
1,505,564
Avg. Vol
404,160
52-wk High
$14.30
52-wk Low
$2.60

Oronsky, Arnold 

Dr. Arnold L. Oronsky, Ph.D., serves as Independent Chairman of the Board of Dynavax Technologies Corporation. Dr. Oronsky has been a member of our Board since November 1996 and became Chairperson of the Board in February 2006. Dr. Oronsky has been a managing director with InterWest Partners, a venture capital firm, since 2009. Prior to joining InterWest Partners in 1994, Dr. Oronsky was Vice President of Discovery Research for the Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976, Dr. Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr. Oronsky also serves as a senior lecturer in the Department of Medicine at The Johns Hopkins Medical School. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr. Oronsky currently serves on the board of directors of KalVista Pharmaceuticals, Inc., a biotechnology company. Dr. Oronsky also served on the board of directors of MacroGenics, Inc., a biopharmaceutical company, from 2000 to 2014, Applied Genetic Technologies Corporation, a biotechnology company, from November 2003 until August 2017, and Tesaro, Inc., an oncology-focused biopharmaceutical company from June 2011 until May 2018. The Board believes that Dr. Oronsky’s significant experience in growing and developing life sciences companies, particularly in the immunology area, provides significant leadership and insights for the Board in defining the strategy of the Company and qualifies him to serve as a director. He received his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University.

Basic Compensation

Total Annual Compensation, USD 75,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 156,767
Fiscal Year Total, USD 231,767

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arnold Oronsky

231,767

David Novack

1,697,590

Ryan Spencer

--

Eddie Gray

4,748,840

Michael Ostrach

3,562,510

Robert Coffman

3,628,280
As Of  31 Dec 2018